Targeted silencing of BAF60a in ApoE-KO mice highlights its potential as a therapeutic target in atherosclerosis, offering a novel strategy to simultaneously modulate lipid metabolism and vascular inflammation for plaque stabilization and regression. This evidence concerns the gene APOE and atherosclerosis.